Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 288

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 288
---
. The loans pursuant to the 2025 Loan Agreements bear interest at a rate of 8%
per annum until maturity. Pursuant to the terms of the 2025 Loan Agreements, we also agreed to pay the lenders an additional risk premium
equal to 50% of their respective loan amount. The loans under the 2025 Loan Agreements mature upon the earlier of August 31, 2025 or
the date of consummation of a Qualified IPO. Furthermore, upon the occurrence of
a Qualified IPO, the Bridge Loan lenders, shall be granted warrants to purchase such number of Ordinary Shares equal to 92,309 Ordinary
Shares following the consummation of this offering.

The sales of the above securities
were deemed to be exempt from registration under the Securities Act because they were made outside of the United States of America to
certain non-U.S. individuals or entities pursuant to Regulation S or, in reliance upon the exemption from registration provided under
Section 4(a)(2) of the Securities Act and the regulations promulgated thereunder.

We claimed exemption from
registration under the Securities Act for the option grants described above under Section 4(a)(2), Regulation S, or under Rule 701
of the Securities Act as transactions pursuant to written compensatory plans or pursuant to a written contract relating to compensation.

No underwriters were employed
in connection with the securities issuances set forth in this Item.

<div align='center'>II-3</div>

Item 8. Exhibits and Financial Statement Schedules.

(a) Exhibits. See the Exhibit Index attached
to this registration statement, which is incorporated by reference herein.

(b) Financial Statement Schedules. Schedules
not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial
statements or notes thereto.

Item 9. Undertakings.

(a) The undersigned Registrant
hereby undertakes:

| (1) | To file, during any period                                                                          
 in which offers or sales are being made, a post-effective amendment to this registration statement: |

| i. | To include any prospectus                                   
 required by section 10(a)(3) of the Securities Act of 1933; |

| ii. | To reflect in the prospectus                                                                                                             
 any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) 
 which, individually or in the aggregate, represent a fundamental change